Key Highlights
● The Russell 2000 rose 12.85 points to close at 2,806.98.
● It lost 25.91 points for the week, a fifth straight decline.
● Smaller companies feel higher borrowing costs more quickly.
● Biotech gains helped, but regional banks and homebuilders were weak.
The Russell 2000 index of smaller companies rose 12.85 points on Friday to close at 2,806.98, according to market data; another reading put the close slightly higher at 2,808.57. Either way, the gain was smaller in relative terms than those of the S&P 500, the Dow and the Nasdaq.
For the week, the Russell 2000 lost 25.91 points. That made it the only major US index to fall over the five sessions, and it marked a fifth straight weekly decline, according to market data. The small-cap benchmark is still up 325.07 points for the year, but the recent run has taken some of the shine off that advance.
Why small caps are feeling the squeeze
Smaller companies tend to rely more on bank loans and floating-rate debt than large corporations, so they feel higher borrowing costs more quickly. That is a problem right now. The Federal Reserve raised rates in September for the first time since 2023, minutes released on Wednesday showed officials saw another increase as likely appropriate by year-end, and Fed Governor Christopher Waller said on Thursday that he anticipates additional hikes to bring inflation back to the Fed's goal.
Meanwhile, the 10-year Treasury yield hovered near a 24-year high reached earlier in the week. Regional banks, a large slice of the small-cap universe, slipped on Friday, and homebuilders were weak as well. Tatiana Darie wrote that the strain from high rates was nowhere more visible than in small caps.
The economic picture adds to the worry. September payrolls rose by just 29,000, well short of forecasts above 80,000, and consumer sentiment fell to a five-month low on Friday. Smaller firms, which are more tied to the domestic economy, are more exposed to a slowdown in household spending.
Where the gains came from
Friday's rise was helped by a rally in biotechnology, where many Russell 2000 members live. A report on a planned NIH-linked public-private initiative to fast-track cancer vaccines lifted vaccine and gene-related names. Novavax (NASDAQ:NVAX) jumped, and Quantum-Si (NASDAQ:QSI) surged after saying its Proteus platform can now identify 19 of the 20 amino acids. Clover Health (NASDAQ:CLOV) rose to $4.79 after its PPO plans received a five-star rating for 2027.
There were sharp losers too. Alignment Healthcare (NASDAQ:ALHC) slid to $7.55 after its largest contract fell below four stars in the government's 2027 Medicare Advantage ratings; company president Dawn Maroney said: "We intend to pursue all available administrative remedies." AST SpaceMobile (NASDAQ:ASTS) fell $5.97 to $50.97 after SpaceX (NASDAQ:SPCX) agreed to buy nationwide spectrum for its Starlink Mobile service.
Rotation has favoured big, defensive names
This week's leadership went to large, defensive sectors. On the S&P 500, utilities, consumer staples, energy and health care posted the best weekly performances, while fund-flow data showed a record $19.78 billion pouring into US bond funds. That is the kind of environment in which smaller, more economically sensitive companies tend to lag.
CPI and Regional Bank Earnings Hold the Key for Small Caps
The September consumer price index on Wednesday, October 14, is the biggest test for small caps, since a hotter reading could firm up bets on a December rate hike. Producer prices and retail sales follow on Thursday. Regional lenders such as First Horizon (NYSE:FHN), Citizens (NYSE:CFG), M&T (NYSE:MTB), Regions (NYSE:RF) and Truist (NYSE:TFC) report results during the week, offering a read on credit conditions. Stocks trade Monday for Columbus Day while bond markets are shut. The Fed meets October 27–28.






Please wait processing your request...